Short Interest in Rafael Holdings, Inc. (NYSE:RFL) Grows By 90.8%

Rafael Holdings, Inc. (NYSE:RFL) saw a significant growth in short interest in June. As of June 30th, there was short interest totaling 133,570 shares, a growth of 90.8% from the June 15th total of 70,015 shares. Based on an average trading volume of 303,935 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.4% of the company’s shares are short sold.

Hedge Funds Weigh In On Rafael

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Marshall Wace LLP bought a new stake in Rafael during the 2nd quarter worth approximately $50,000. Renaissance Technologies LLC raised its position in shares of Rafael by 59.1% during the first quarter. Renaissance Technologies LLC now owns 89,138 shares of the company’s stock worth $111,000 after acquiring an additional 33,111 shares during the last quarter. Citadel Advisors LLC boosted its holdings in Rafael by 132.3% in the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock valued at $99,000 after acquiring an additional 41,335 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Rafael by 25.4% in the 4th quarter. Geode Capital Management LLC now owns 445,866 shares of the company’s stock worth $526,000 after purchasing an additional 90,417 shares during the period. Finally, Cable Car Capital LP acquired a new stake in shares of Rafael during the second quarter worth $173,000. Institutional investors and hedge funds own 11.30% of the company’s stock.

Rafael Stock Performance

Shares of NYSE RFL traded down $0.20 during mid-day trading on Friday, reaching $2.15. The company had a trading volume of 84,344 shares, compared to its average volume of 132,371. Rafael has a one year low of $1.12 and a one year high of $3.96. The firm has a market cap of $111.90 million, a price-to-earnings ratio of -3.16 and a beta of 0.29. The business’s 50-day simple moving average is $2.06 and its 200 day simple moving average is $1.55.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 28th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.